R. 1. Conrad, M. Angeli, J. P. Vandenabeele, P. Stockwell, and B. R. , Regulated necrosis: disease relevance and therapeutic opportunities, Nature Reviews Drug Discovery, vol.2, issue.5, pp.348-366, 2016.
DOI : 10.1038/nchembio809

A. Degterev, Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury, Nature Chemical Biology, vol.57, issue.2, pp.112-119, 2005.
DOI : 10.1016/S0896-6273(03)00601-9

A. Degterev, Identification of RIP1 kinase as a specific cellular target of necrostatins, Nature Chemical Biology, vol.4, issue.5, pp.313-321, 2008.
DOI : 10.1016/j.bbagen.2006.11.011

T. Vanden-berghe, A. Linkermann, S. Jouan-lanhouet, H. Walczak, and P. Vandenabeele, Regulated necrosis: the expanding network of non-apoptotic cell death pathways, Nature Reviews Molecular Cell Biology, vol.24, issue.2, pp.135-147, 2014.
DOI : 10.1038/cr.2013.171

B. Miao and A. Degterev, Methods to Analyze Cellular Necroptosis, Methods Mol. Biol, vol.559, pp.79-93, 2009.
DOI : 10.1007/978-1-60327-017-5_6

S. Jouan-lanhouet, Necroptosis, in vivo detection in experimental disease models, Seminars in Cell & Developmental Biology, vol.35, pp.2-13, 2014.
DOI : 10.1016/j.semcdb.2014.08.010

T. Vanden-berghe, B. Hassannia, and P. Vandenabeele, An outline of necrosome triggers, Cellular and Molecular Life Sciences, vol.5, issue.6, pp.2137-2152, 2016.
DOI : 10.1038/cddis.2014.347

B. Strilic, Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis, Nature, vol.25, issue.7615, pp.215-218, 2016.
DOI : 10.1016/j.devcel.2013.04.008

X. Teng, Structure???activity relationship study of novel necroptosis inhibitors, Bioorganic & Medicinal Chemistry Letters, vol.15, issue.22, pp.5039-5044, 2005.
DOI : 10.1016/j.bmcl.2005.07.077

P. A. Harris, Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis, ACS Medicinal Chemistry Letters, vol.4, issue.12, pp.1238-1243, 2013.
DOI : 10.1021/ml400382p

M. Najjar, Structure Guided Design of Potent and Selective Ponatinib-Based Hybrid Inhibitors for RIPK1, Cell Reports, vol.10, issue.11, pp.1850-1860, 2015.
DOI : 10.1016/j.celrep.2015.02.052

A. Fauster, A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis, Cell Death and Disease, vol.62, issue.5, 1767.
DOI : 10.1021/pr100795z

P. A. Harris, ][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors, Journal of Medicinal Chemistry, vol.59, issue.5, pp.2163-2178, 2016.
DOI : 10.1021/acs.jmedchem.5b01898

S. B. Berger, Characterization of GSK???963: a structurally distinct, potent and selective inhibitor of RIP1 kinase, Cell Death Discovery, vol.1, 2015.
DOI : 10.1038/cddiscovery.2015.9

Y. Ren, Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome, Journal of Medicinal Chemistry, vol.60, issue.3, pp.972-986, 2017.
DOI : 10.1021/acs.jmedchem.6b01196

P. A. Harris, Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases, Journal of Medicinal Chemistry, vol.60, issue.4, pp.1247-1261, 2017.
DOI : 10.1021/acs.jmedchem.6b01751

M. Chadenson, M. Hauteville, and J. Chopin, Synthesis of 2,5-dihydroxy-7-methoxyflavanone, cyclic structure of the benzoyl-(2,6-dihydroxy-4-methoxybenzoyl)-methane from Populus nigra buds, Journal of the Chemical Society, Chemical Communications, issue.2, pp.107-108, 1972.
DOI : 10.1039/c3972000107b

T. Xie, Structural Basis of RIP1 Inhibition by Necrostatins, Structure, vol.21, issue.3, pp.493-499, 2013.
DOI : 10.1016/j.str.2013.01.016

D. J. Newman and G. M. Cragg, Natural Products as Sources of New Drugs from 1981 to 2014, Journal of Natural Products, vol.79, issue.3, pp.629-661, 2016.
DOI : 10.1021/acs.jnatprod.5b01055

A. Degterev and A. Linkermann, Generation of small molecules to interfere with regulated necrosis, Cellular and Molecular Life Sciences, vol.5, issue.4, pp.2251-2267, 2016.
DOI : 10.1016/j.celrep.2013.10.034

M. Hauteville, J. Chopin, H. Geiger, and L. Schuler, Protogenkwanin, a new flavonoid from equisetum arvense L, Tetrahedron, vol.37, issue.2, pp.377-381, 1981.
DOI : 10.1016/S0040-4020(01)92024-1

L. Cann and F. , Sibiriline, a new small chemical inhibitor of Receptor-Interacting Protein Kinase 1, prevents immune-dependent hepatitis, FEBS J, p.14176, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01616420

M. A. Fabian, A small molecule???kinase interaction map for clinical kinase inhibitors, Nature Biotechnology, vol.10, issue.3, pp.329-336, 2005.
DOI : 10.1073/pnas.0405220101

M. W. Karaman, A quantitative analysis of kinase inhibitor selectivity, Nature Biotechnology, vol.50, issue.1, pp.127-132, 2008.
DOI : 10.1021/jm070562u